News | January 27, 2022
Moderna working on Omicron-specific booster candidate
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
It meets stringent requirements for ensuring the safe storage and efficacy of temperature-sensitive vaccines, including those for Covid-19
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during clinical trials
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Subscribe To Our Newsletter & Stay Updated
